From the Research
The Pipeline flow-diverting stent demonstrates occlusion rates of approximately 81.8% at 1 year for brain aneurysms, as shown in the most recent and highest quality study 1. This device works by redirecting blood flow away from the aneurysm sac, promoting stagnation and thrombosis within the aneurysm while maintaining patency of the parent vessel and branch arteries. Complete occlusion typically develops progressively over time, with initial partial occlusion often observed at 3-6 months and increasing to higher rates by the 12-month mark. Factors affecting occlusion rates include aneurysm size, location, morphology, and neck width, with smaller aneurysms and those with narrower necks generally achieving higher occlusion rates. Some key points to consider when using the Pipeline flow-diverting stent include:
- Patients receiving Pipeline stents require dual antiplatelet therapy (typically aspirin 325mg daily and clopidogrel 75mg daily) for at least 3-6 months post-procedure to prevent thromboembolic complications while the device endothelializes 1.
- Regular imaging follow-up with either DSA (digital subtraction angiography), CTA, or MRA is essential to monitor occlusion status, with the first follow-up typically scheduled at 6 months and then at 12 months post-procedure 1.
- The Pipeline flow-diverting stent has been shown to be a safe and effective treatment for intracranial aneurysms, with low rates of major stroke and neurologic death 2, 1.
- The application of a flow diverter specific occlusion classification has been shown to attest the long-term durability of the Pipeline flow-diverting stent, with higher rates of successful aneurysm occlusion and no documented aneurysm rupture 2.